Drugs / PP405
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06393452 | Jun 2024 → Jul 2025 | androgenetic alopecia | Pelage Pharmaceuticals, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-06-17 | Pelage Pharmaceuticals, Inc. | Results Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy pelagepharma.com ↗
Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 — a topical therapy for androgenetic alopecia advancing through the FDA clinical development pathway. |
| 2024-03-09 | Pelage Pharmaceuticals, Inc. | Results Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study pelagepharma.com ↗
Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, today presented positive translational and Phase 1 clinical data demonstrating the company’s novel small molecule therapy PP405 reactivates dormant hair follicle stem cells to trigger hair growth. |
| 2024-02-27 | Pelage Pharmaceuticals, Inc. | Results Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss pelagepharma.com ↗
We are pleased to announce that we have completed a first-in-human Phase 1 clinical trial that demonstrated seven days of topical dosing with PP405 was safe and well-tolerated, and showed statistically significant activation of hair follicle stem cells. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Pelage Pharmaceuticals, Inc. | Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 pelagepharma.com ↗ |
| 2025-06-17 | Pelage Pharmaceuticals, Inc. | Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy pelagepharma.com ↗ |
| 2024-03-09 | Pelage Pharmaceuticals, Inc. | Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study pelagepharma.com ↗ |
| 2024-02-27 | Pelage Pharmaceuticals, Inc. | Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss pelagepharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PP405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06393452 ↗ |
| Action | Inhibit | “PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)” NCT06393452 ↗ |
| Route | Topical | “0.05% Topical Gel applied once daily” NCT06393452 ↗ |